nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—attention deficit hyperactivity disorder—Clonidine—glaucoma	0.413	1	CpDpCtD
Methamphetamine—ADRA2C—Apraclonidine—glaucoma	0.046	0.096	CbGbCtD
Methamphetamine—ADRA2C—Brimonidine—glaucoma	0.046	0.096	CbGbCtD
Methamphetamine—ADRA2B—Brimonidine—glaucoma	0.0437	0.091	CbGbCtD
Methamphetamine—ADRA2B—Apraclonidine—glaucoma	0.0437	0.091	CbGbCtD
Methamphetamine—ADRA2C—Dipivefrin—glaucoma	0.0368	0.0767	CbGbCtD
Methamphetamine—ADRA2B—Dipivefrin—glaucoma	0.0349	0.0728	CbGbCtD
Methamphetamine—ADRA2A—Brimonidine—glaucoma	0.0304	0.0633	CbGbCtD
Methamphetamine—ADRA2A—Apraclonidine—glaucoma	0.0304	0.0633	CbGbCtD
Methamphetamine—SLC22A3—Clonidine—glaucoma	0.0282	0.0589	CbGbCtD
Methamphetamine—ADRA2A—Dipivefrin—glaucoma	0.0243	0.0506	CbGbCtD
Methamphetamine—ADRA2C—Clonidine—glaucoma	0.0191	0.0399	CbGbCtD
Methamphetamine—ADRA2B—Clonidine—glaucoma	0.0181	0.0378	CbGbCtD
Methamphetamine—SLC22A5—Clonidine—glaucoma	0.0175	0.0366	CbGbCtD
Methamphetamine—SLC6A2—Clonidine—glaucoma	0.014	0.0292	CbGbCtD
Methamphetamine—ADRA2A—Clonidine—glaucoma	0.0126	0.0263	CbGbCtD
Methamphetamine—CYP2D6—Carteolol—glaucoma	0.0113	0.0236	CbGbCtD
Methamphetamine—CYP2D6—Betaxolol—glaucoma	0.00765	0.016	CbGbCtD
Methamphetamine—CYP2D6—Methazolamide—glaucoma	0.0058	0.0121	CbGbCtD
Methamphetamine—CYP2D6—Timolol—glaucoma	0.00493	0.0103	CbGbCtD
Methamphetamine—CYP2D6—Clonidine—glaucoma	0.00419	0.00874	CbGbCtD
Methamphetamine—Digestion impaired—Diclofenamide—glaucoma	0.00262	0.0449	CcSEcCtD
Methamphetamine—Digestion impaired—Methazolamide—glaucoma	0.00241	0.0414	CcSEcCtD
Methamphetamine—Digestion impaired—Acetazolamide—glaucoma	0.00167	0.0286	CcSEcCtD
Methamphetamine—Digestion impaired—Brinzolamide—glaucoma	0.00151	0.0258	CcSEcCtD
Methamphetamine—Tachycardia—Dipivefrin—glaucoma	0.00119	0.0204	CcSEcCtD
Methamphetamine—Erectile dysfunction—Levobunolol—glaucoma	0.000973	0.0167	CcSEcCtD
Methamphetamine—Hypersensitivity—Dipivefrin—glaucoma	0.0009	0.0154	CcSEcCtD
Methamphetamine—Palpitations—Metipranolol—glaucoma	0.000743	0.0127	CcSEcCtD
Methamphetamine—Tremor—Diclofenamide—glaucoma	0.000718	0.0123	CcSEcCtD
Methamphetamine—Palpitations—Carteolol—glaucoma	0.000688	0.0118	CcSEcCtD
Methamphetamine—Palpitations—Levobunolol—glaucoma	0.000651	0.0112	CcSEcCtD
Methamphetamine—Erectile dysfunction—Dorzolamide—glaucoma	0.000591	0.0101	CcSEcCtD
Methamphetamine—Erectile dysfunction—Brinzolamide—glaucoma	0.000581	0.00997	CcSEcCtD
Methamphetamine—Insomnia—Carteolol—glaucoma	0.000575	0.00986	CcSEcCtD
Methamphetamine—Dyspepsia—Diclofenamide—glaucoma	0.00055	0.00944	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Diclofenamide—glaucoma	0.00054	0.00925	CcSEcCtD
Methamphetamine—Dyspepsia—Carbachol—glaucoma	0.000537	0.00921	CcSEcCtD
Methamphetamine—Constipation—Diclofenamide—glaucoma	0.000535	0.00917	CcSEcCtD
Methamphetamine—Dyspepsia—Methazolamide—glaucoma	0.000507	0.00869	CcSEcCtD
Methamphetamine—Hypersensitivity—Metipranolol—glaucoma	0.000506	0.00867	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Methazolamide—glaucoma	0.000497	0.00852	CcSEcCtD
Methamphetamine—Palpitations—Apraclonidine—glaucoma	0.000482	0.00827	CcSEcCtD
Methamphetamine—Urticaria—Levobunolol—glaucoma	0.000477	0.00818	CcSEcCtD
Methamphetamine—Psychotic disorder—Betaxolol—glaucoma	0.000477	0.00817	CcSEcCtD
Methamphetamine—Hypersensitivity—Carteolol—glaucoma	0.000468	0.00803	CcSEcCtD
Methamphetamine—Palpitations—Bimatoprost—glaucoma	0.000468	0.00802	CcSEcCtD
Methamphetamine—Urticaria—Methazolamide—glaucoma	0.000457	0.00784	CcSEcCtD
Methamphetamine—Dizziness—Metipranolol—glaucoma	0.000454	0.00778	CcSEcCtD
Methamphetamine—Agitation—Acetazolamide—glaucoma	0.000449	0.00769	CcSEcCtD
Methamphetamine—Erectile dysfunction—Clonidine—glaucoma	0.000446	0.00765	CcSEcCtD
Methamphetamine—Hypersensitivity—Levobunolol—glaucoma	0.000443	0.00759	CcSEcCtD
Methamphetamine—Headache—Metipranolol—glaucoma	0.00043	0.00737	CcSEcCtD
Methamphetamine—Dizziness—Carteolol—glaucoma	0.00042	0.00721	CcSEcCtD
Methamphetamine—Diarrhoea—Carbachol—glaucoma	0.000417	0.00716	CcSEcCtD
Methamphetamine—Palpitations—Brimonidine—glaucoma	0.000414	0.0071	CcSEcCtD
Methamphetamine—Dizziness—Diclofenamide—glaucoma	0.000413	0.00709	CcSEcCtD
Methamphetamine—Tremor—Brinzolamide—glaucoma	0.000412	0.00707	CcSEcCtD
Methamphetamine—Diarrhoea—Levobunolol—glaucoma	0.000411	0.00705	CcSEcCtD
Methamphetamine—Agitation—Brinzolamide—glaucoma	0.000404	0.00693	CcSEcCtD
Methamphetamine—Dizziness—Carbachol—glaucoma	0.000403	0.00692	CcSEcCtD
Methamphetamine—Insomnia—Apraclonidine—glaucoma	0.000403	0.00691	CcSEcCtD
Methamphetamine—Headache—Carteolol—glaucoma	0.000398	0.00683	CcSEcCtD
Methamphetamine—Dizziness—Levobunolol—glaucoma	0.000397	0.00681	CcSEcCtD
Methamphetamine—Tremor—Pilocarpine—glaucoma	0.000396	0.00679	CcSEcCtD
Methamphetamine—Palpitations—Dorzolamide—glaucoma	0.000395	0.00678	CcSEcCtD
Methamphetamine—Lacosamide—CA1—glaucoma	0.000394	0.446	CrCbGaD
Methamphetamine—Diarrhoea—Methazolamide—glaucoma	0.000394	0.00675	CcSEcCtD
Methamphetamine—Palpitations—Travoprost—glaucoma	0.000394	0.00675	CcSEcCtD
Methamphetamine—Headache—Diclofenamide—glaucoma	0.000392	0.00672	CcSEcCtD
Methamphetamine—Insomnia—Bimatoprost—glaucoma	0.000391	0.0067	CcSEcCtD
Methamphetamine—Palpitations—Brinzolamide—glaucoma	0.000389	0.00667	CcSEcCtD
Methamphetamine—Erectile dysfunction—Betaxolol—glaucoma	0.000389	0.00666	CcSEcCtD
Methamphetamine—Agitation—Pilocarpine—glaucoma	0.000389	0.00666	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Apraclonidine—glaucoma	0.000385	0.00659	CcSEcCtD
Methamphetamine—Headache—Carbachol—glaucoma	0.000382	0.00655	CcSEcCtD
Methamphetamine—Constipation—Apraclonidine—glaucoma	0.000381	0.00653	CcSEcCtD
Methamphetamine—Dyspepsia—Bimatoprost—glaucoma	0.00038	0.00652	CcSEcCtD
Methamphetamine—Headache—Levobunolol—glaucoma	0.000376	0.00645	CcSEcCtD
Methamphetamine—Palpitations—Pilocarpine—glaucoma	0.000374	0.00641	CcSEcCtD
Methamphetamine—Tachycardia—Brimonidine—glaucoma	0.000373	0.0064	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Bimatoprost—glaucoma	0.000373	0.00639	CcSEcCtD
Methamphetamine—Dizziness—Latanoprost—glaucoma	0.000368	0.00632	CcSEcCtD
Methamphetamine—Headache—Methazolamide—glaucoma	0.000361	0.00618	CcSEcCtD
Methamphetamine—Tachycardia—Travoprost—glaucoma	0.000355	0.00609	CcSEcCtD
Methamphetamine—Dyspepsia—Acetazolamide—glaucoma	0.000351	0.00601	CcSEcCtD
Methamphetamine—Tachycardia—Brinzolamide—glaucoma	0.00035	0.00601	CcSEcCtD
Methamphetamine—Headache—Latanoprost—glaucoma	0.000349	0.00599	CcSEcCtD
Methamphetamine—Insomnia—Brimonidine—glaucoma	0.000346	0.00593	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000344	0.0059	CcSEcCtD
Methamphetamine—Tachycardia—Pilocarpine—glaucoma	0.000337	0.00578	CcSEcCtD
Methamphetamine—Dyspepsia—Brimonidine—glaucoma	0.000337	0.00577	CcSEcCtD
Methamphetamine—Insomnia—Dorzolamide—glaucoma	0.00033	0.00566	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Brimonidine—glaucoma	0.00033	0.00566	CcSEcCtD
Methamphetamine—Hypersensitivity—Apraclonidine—glaucoma	0.000328	0.00563	CcSEcCtD
Methamphetamine—Insomnia—Brinzolamide—glaucoma	0.000325	0.00557	CcSEcCtD
Methamphetamine—Dyspepsia—Dorzolamide—glaucoma	0.000321	0.00551	CcSEcCtD
Methamphetamine—Dyspepsia—Travoprost—glaucoma	0.00032	0.00549	CcSEcCtD
Methamphetamine—Erectile dysfunction—Timolol—glaucoma	0.000317	0.00544	CcSEcCtD
Methamphetamine—Urticaria—Acetazolamide—glaucoma	0.000317	0.00543	CcSEcCtD
Methamphetamine—Tremor—Clonidine—glaucoma	0.000316	0.00542	CcSEcCtD
Methamphetamine—Dyspepsia—Brinzolamide—glaucoma	0.000316	0.00542	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Travoprost—glaucoma	0.000314	0.00538	CcSEcCtD
Methamphetamine—Insomnia—Pilocarpine—glaucoma	0.000312	0.00535	CcSEcCtD
Methamphetamine—Constipation—Travoprost—glaucoma	0.000311	0.00533	CcSEcCtD
Methamphetamine—Agitation—Clonidine—glaucoma	0.00031	0.00532	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Brinzolamide—glaucoma	0.00031	0.00532	CcSEcCtD
Methamphetamine—Diarrhoea—Apraclonidine—glaucoma	0.000305	0.00523	CcSEcCtD
Methamphetamine—Dyspepsia—Pilocarpine—glaucoma	0.000304	0.00521	CcSEcCtD
Methamphetamine—Lacosamide—CA2—glaucoma	0.000299	0.338	CrCbGaD
Methamphetamine—Palpitations—Clonidine—glaucoma	0.000298	0.00512	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000298	0.00511	CcSEcCtD
Methamphetamine—Constipation—Pilocarpine—glaucoma	0.000295	0.00506	CcSEcCtD
Methamphetamine—Dizziness—Apraclonidine—glaucoma	0.000295	0.00505	CcSEcCtD
Methamphetamine—Urticaria—Dorzolamide—glaucoma	0.00029	0.00497	CcSEcCtD
Methamphetamine—Dizziness—Bimatoprost—glaucoma	0.000286	0.0049	CcSEcCtD
Methamphetamine—Urticaria—Brinzolamide—glaucoma	0.000285	0.00489	CcSEcCtD
Methamphetamine—Hypersensitivity—Brimonidine—glaucoma	0.000282	0.00483	CcSEcCtD
Methamphetamine—Headache—Apraclonidine—glaucoma	0.000279	0.00478	CcSEcCtD
Methamphetamine—Tremor—Betaxolol—glaucoma	0.000275	0.00472	CcSEcCtD
Methamphetamine—Diarrhoea—Acetazolamide—glaucoma	0.000273	0.00467	CcSEcCtD
Methamphetamine—Headache—Bimatoprost—glaucoma	0.000271	0.00464	CcSEcCtD
Methamphetamine—Hypersensitivity—Dorzolamide—glaucoma	0.000269	0.00461	CcSEcCtD
Methamphetamine—Tachycardia—Clonidine—glaucoma	0.000269	0.00461	CcSEcCtD
Methamphetamine—Hypersensitivity—Travoprost—glaucoma	0.000268	0.00459	CcSEcCtD
Methamphetamine—Hypersensitivity—Brinzolamide—glaucoma	0.000265	0.00454	CcSEcCtD
Methamphetamine—Dizziness—Acetazolamide—glaucoma	0.000263	0.00452	CcSEcCtD
Methamphetamine—Palpitations—Betaxolol—glaucoma	0.00026	0.00445	CcSEcCtD
Methamphetamine—Hypersensitivity—Pilocarpine—glaucoma	0.000254	0.00436	CcSEcCtD
Methamphetamine—Dizziness—Brimonidine—glaucoma	0.000253	0.00434	CcSEcCtD
Methamphetamine—Diarrhoea—Dorzolamide—glaucoma	0.00025	0.00428	CcSEcCtD
Methamphetamine—Headache—Acetazolamide—glaucoma	0.00025	0.00428	CcSEcCtD
Methamphetamine—Insomnia—Clonidine—glaucoma	0.000249	0.00427	CcSEcCtD
Methamphetamine—Diarrhoea—Travoprost—glaucoma	0.000249	0.00427	CcSEcCtD
Methamphetamine—Diarrhoea—Brinzolamide—glaucoma	0.000246	0.00421	CcSEcCtD
Methamphetamine—Dizziness—Dorzolamide—glaucoma	0.000241	0.00414	CcSEcCtD
Methamphetamine—Dizziness—Travoprost—glaucoma	0.00024	0.00412	CcSEcCtD
Methamphetamine—Headache—Brimonidine—glaucoma	0.00024	0.00411	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Clonidine—glaucoma	0.000238	0.00408	CcSEcCtD
Methamphetamine—Dizziness—Brinzolamide—glaucoma	0.000237	0.00407	CcSEcCtD
Methamphetamine—Diarrhoea—Pilocarpine—glaucoma	0.000236	0.00405	CcSEcCtD
Methamphetamine—Constipation—Clonidine—glaucoma	0.000236	0.00404	CcSEcCtD
Methamphetamine—Tachycardia—Betaxolol—glaucoma	0.000234	0.00402	CcSEcCtD
Methamphetamine—Headache—Dorzolamide—glaucoma	0.000229	0.00392	CcSEcCtD
Methamphetamine—Dizziness—Pilocarpine—glaucoma	0.000228	0.00391	CcSEcCtD
Methamphetamine—Headache—Travoprost—glaucoma	0.000228	0.00391	CcSEcCtD
Methamphetamine—Headache—Brinzolamide—glaucoma	0.000225	0.00386	CcSEcCtD
Methamphetamine—Urticaria—Clonidine—glaucoma	0.000219	0.00375	CcSEcCtD
Methamphetamine—Insomnia—Betaxolol—glaucoma	0.000217	0.00372	CcSEcCtD
Methamphetamine—Headache—Pilocarpine—glaucoma	0.000216	0.00371	CcSEcCtD
Methamphetamine—Palpitations—Timolol—glaucoma	0.000212	0.00364	CcSEcCtD
Methamphetamine—Dyspepsia—Betaxolol—glaucoma	0.000211	0.00362	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Betaxolol—glaucoma	0.000207	0.00355	CcSEcCtD
Methamphetamine—Constipation—Betaxolol—glaucoma	0.000205	0.00352	CcSEcCtD
Methamphetamine—Hypersensitivity—Clonidine—glaucoma	0.000203	0.00348	CcSEcCtD
Methamphetamine—Urticaria—Betaxolol—glaucoma	0.000191	0.00327	CcSEcCtD
Methamphetamine—Pseudoephedrine—TNF—glaucoma	0.00019	0.216	CrCbGaD
Methamphetamine—Diarrhoea—Clonidine—glaucoma	0.000189	0.00323	CcSEcCtD
Methamphetamine—Dizziness—Clonidine—glaucoma	0.000182	0.00312	CcSEcCtD
Methamphetamine—Insomnia—Timolol—glaucoma	0.000177	0.00304	CcSEcCtD
Methamphetamine—Hypersensitivity—Betaxolol—glaucoma	0.000177	0.00303	CcSEcCtD
Methamphetamine—Headache—Clonidine—glaucoma	0.000173	0.00296	CcSEcCtD
Methamphetamine—Dyspepsia—Timolol—glaucoma	0.000173	0.00296	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Timolol—glaucoma	0.000169	0.0029	CcSEcCtD
Methamphetamine—Diarrhoea—Betaxolol—glaucoma	0.000164	0.00281	CcSEcCtD
Methamphetamine—Dizziness—Betaxolol—glaucoma	0.000159	0.00272	CcSEcCtD
Methamphetamine—Urticaria—Timolol—glaucoma	0.000156	0.00267	CcSEcCtD
Methamphetamine—Headache—Betaxolol—glaucoma	0.00015	0.00258	CcSEcCtD
Methamphetamine—Hypersensitivity—Timolol—glaucoma	0.000144	0.00248	CcSEcCtD
Methamphetamine—Diarrhoea—Timolol—glaucoma	0.000134	0.0023	CcSEcCtD
Methamphetamine—Dizziness—Timolol—glaucoma	0.00013	0.00222	CcSEcCtD
Methamphetamine—Headache—Timolol—glaucoma	0.000123	0.00211	CcSEcCtD
Methamphetamine—TAAR1—Signaling Pathways—SMO—glaucoma	3.5e-05	0.000724	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CTSA—glaucoma	3.5e-05	0.000724	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A1—glaucoma	3.45e-05	0.000713	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—C3—glaucoma	3.41e-05	0.000706	CbGpPWpGaD
Methamphetamine—CYP2D6—Biological oxidations—GSTT1—glaucoma	3.41e-05	0.000705	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—OPN4—glaucoma	3.35e-05	0.000694	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—PTGFR—glaucoma	3.33e-05	0.000688	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CA2—glaucoma	3.3e-05	0.000683	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—PTGFR—glaucoma	3.23e-05	0.000669	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—NTRK2—glaucoma	3.2e-05	0.000662	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—SMO—glaucoma	3.18e-05	0.000657	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—LRP12—glaucoma	3.06e-05	0.000633	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC6A1—glaucoma	3.05e-05	0.000631	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—SOD1—glaucoma	3.04e-05	0.000629	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—C3—glaucoma	3.02e-05	0.000625	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—PTGFR—glaucoma	3.02e-05	0.000625	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—OPN4—glaucoma	3e-05	0.000621	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—SMO—glaucoma	2.97e-05	0.000614	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—glaucoma	2.92e-05	0.000604	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—LRP12—glaucoma	2.86e-05	0.000591	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—C3—glaucoma	2.82e-05	0.000584	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—FN1—glaucoma	2.79e-05	0.000577	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—TXN—glaucoma	2.75e-05	0.000569	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	2.75e-05	0.000569	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—NGFR—glaucoma	2.75e-05	0.000568	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—OPN4—glaucoma	2.72e-05	0.000564	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—TGFB2—glaucoma	2.72e-05	0.000563	CbGpPWpGaD
Methamphetamine—CYP2D6—Biological oxidations—CYP1B1—glaucoma	2.71e-05	0.000562	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PTGFR—glaucoma	2.7e-05	0.000559	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CA1—glaucoma	2.68e-05	0.000554	CbGpPWpGaD
Methamphetamine—CYP2D6—Metapathway biotransformation—CYP1B1—glaucoma	2.68e-05	0.000554	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—NTRK1—glaucoma	2.61e-05	0.00054	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—FN1—glaucoma	2.6e-05	0.000539	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CTSA—glaucoma	2.59e-05	0.000537	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	2.57e-05	0.000532	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—TGFB2—glaucoma	2.54e-05	0.000526	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—TNF—glaucoma	2.5e-05	0.000518	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PTGFR—glaucoma	2.45e-05	0.000507	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CA2—glaucoma	2.45e-05	0.000507	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—SMO—glaucoma	2.41e-05	0.000499	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CDKN2B—glaucoma	2.4e-05	0.000497	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	2.4e-05	0.000497	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—VEGFA—glaucoma	2.39e-05	0.000495	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CA5A—glaucoma	2.39e-05	0.000494	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NARFL—glaucoma	2.39e-05	0.000494	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—TXN—glaucoma	2.33e-05	0.000481	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—LRP12—glaucoma	2.32e-05	0.00048	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—EDN1—glaucoma	2.31e-05	0.000477	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—C3—glaucoma	2.29e-05	0.000474	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	2.24e-05	0.000464	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CA1—glaucoma	2.2e-05	0.000456	CbGpPWpGaD
Methamphetamine—CYP2D6—Biological oxidations—GSTM1—glaucoma	2.17e-05	0.000449	CbGpPWpGaD
Methamphetamine—CYP2D6—Metapathway biotransformation—GSTM1—glaucoma	2.14e-05	0.000443	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CTSA—glaucoma	2.13e-05	0.000441	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—GSTT1—glaucoma	2.13e-05	0.000441	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—OPN4—glaucoma	2.12e-05	0.000439	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—NGF—glaucoma	2.12e-05	0.000439	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—FN1—glaucoma	2.11e-05	0.000437	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—EDN1—glaucoma	2.09e-05	0.000433	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	2.09e-05	0.000432	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TGFB2—glaucoma	2.07e-05	0.000427	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—SOD1—glaucoma	2.06e-05	0.000427	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—TNF—glaucoma	2.05e-05	0.000424	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—C3—glaucoma	2.02e-05	0.000417	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CA2—glaucoma	2.01e-05	0.000417	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—OPN4—glaucoma	1.98e-05	0.00041	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HEYL—glaucoma	1.97e-05	0.000408	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—EDN1—glaucoma	1.96e-05	0.000405	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—SOD1—glaucoma	1.93e-05	0.000399	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PTGFR—glaucoma	1.91e-05	0.000395	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—APOE—glaucoma	1.88e-05	0.000388	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CAV1—glaucoma	1.86e-05	0.000385	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HEYL—glaucoma	1.84e-05	0.000381	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—C3—glaucoma	1.83e-05	0.000379	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	1.82e-05	0.000377	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GSTT1—glaucoma	1.8e-05	0.000373	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—TP53—glaucoma	1.8e-05	0.000373	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CA1—glaucoma	1.79e-05	0.00037	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PTGFR—glaucoma	1.78e-05	0.000369	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—FN1—glaucoma	1.77e-05	0.000366	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—BAD—glaucoma	1.75e-05	0.000362	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CTSA—glaucoma	1.73e-05	0.000359	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—TXN—glaucoma	1.73e-05	0.000357	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—C3—glaucoma	1.71e-05	0.000354	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CYP1B1—glaucoma	1.7e-05	0.000352	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—ABCA1—glaucoma	1.7e-05	0.000352	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CA2—glaucoma	1.64e-05	0.000339	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—SMO—glaucoma	1.63e-05	0.000337	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—OPN4—glaucoma	1.61e-05	0.000333	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—glaucoma	1.59e-05	0.00033	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—EDN1—glaucoma	1.59e-05	0.000329	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—MMP1—glaucoma	1.57e-05	0.000326	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—SOD1—glaucoma	1.57e-05	0.000324	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—SMO—glaucoma	1.52e-05	0.000315	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—CAV1—glaucoma	1.51e-05	0.000312	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HEYL—glaucoma	1.5e-05	0.00031	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RPTOR—glaucoma	1.49e-05	0.000309	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—glaucoma	1.49e-05	0.000308	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—MMP1—glaucoma	1.47e-05	0.000304	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PTGFR—glaucoma	1.45e-05	0.0003	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NCK2—glaucoma	1.45e-05	0.000299	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—ABCA1—glaucoma	1.44e-05	0.000297	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CYP1B1—glaucoma	1.44e-05	0.000297	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—FN1—glaucoma	1.44e-05	0.000297	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—TXN—glaucoma	1.42e-05	0.000294	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—CAV1—glaucoma	1.41e-05	0.000292	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—NOS3—glaucoma	1.41e-05	0.000291	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RPTOR—glaucoma	1.4e-05	0.000289	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—C3—glaucoma	1.39e-05	0.000287	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—GSTM1—glaucoma	1.36e-05	0.000281	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NCK2—glaucoma	1.35e-05	0.00028	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—FN1—glaucoma	1.34e-05	0.000278	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GSTT1—glaucoma	1.34e-05	0.000277	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—SMO—glaucoma	1.24e-05	0.000256	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HDAC9—glaucoma	1.23e-05	0.000255	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CDKN1B—glaucoma	1.22e-05	0.000252	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—glaucoma	1.21e-05	0.00025	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—MTHFR—glaucoma	1.2e-05	0.000248	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—MMP1—glaucoma	1.19e-05	0.000247	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—EDN1—glaucoma	1.18e-05	0.000245	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CA1—glaucoma	1.17e-05	0.000241	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—TXN—glaucoma	1.15e-05	0.000239	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HDAC9—glaucoma	1.15e-05	0.000238	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GSTM1—glaucoma	1.15e-05	0.000238	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—CAV1—glaucoma	1.14e-05	0.000237	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—NOS3—glaucoma	1.14e-05	0.000236	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RPTOR—glaucoma	1.13e-05	0.000235	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CTSA—glaucoma	1.13e-05	0.000234	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—MMP9—glaucoma	1.13e-05	0.000233	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—APOE—glaucoma	1.12e-05	0.000231	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CAV1—glaucoma	1.11e-05	0.000229	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—EDN1—glaucoma	1.11e-05	0.000229	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GSTT1—glaucoma	1.1e-05	0.000228	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NCK2—glaucoma	1.1e-05	0.000227	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—FN1—glaucoma	1.09e-05	0.000225	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—EDN1—glaucoma	1.07e-05	0.000222	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CA2—glaucoma	1.07e-05	0.000221	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CYP1B1—glaucoma	1.07e-05	0.000221	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—ABCA1—glaucoma	1.07e-05	0.000221	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—NOS3—glaucoma	1.07e-05	0.000221	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—C3—glaucoma	1.03e-05	0.000214	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—MTHFR—glaucoma	1.02e-05	0.00021	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—VEGFA—glaucoma	1.01e-05	0.00021	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—EDN1—glaucoma	1e-05	0.000208	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—C3—glaucoma	9.66e-06	0.0002	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SMO—glaucoma	9.63e-06	0.000199	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—APOE—glaucoma	9.45e-06	0.000196	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—C3—glaucoma	9.39e-06	0.000194	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CAV1—glaucoma	9.37e-06	0.000194	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HDAC9—glaucoma	9.34e-06	0.000193	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SMO—glaucoma	8.99e-06	0.000186	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—EDN1—glaucoma	8.98e-06	0.000186	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSTT1—glaucoma	8.94e-06	0.000185	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NTRK2—glaucoma	8.81e-06	0.000182	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—C3—glaucoma	8.77e-06	0.000181	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CYP1B1—glaucoma	8.77e-06	0.000181	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ABCA1—glaucoma	8.77e-06	0.000181	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—NOS3—glaucoma	8.66e-06	0.000179	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GSTM1—glaucoma	8.52e-06	0.000176	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—NOS3—glaucoma	8.37e-06	0.000173	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NTRK2—glaucoma	8.23e-06	0.00017	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—VEGFA—glaucoma	8.22e-06	0.00017	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—EDN1—glaucoma	8.15e-06	0.000169	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—C3—glaucoma	7.84e-06	0.000162	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—VEGFA—glaucoma	7.68e-06	0.000159	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PTGS2—glaucoma	7.66e-06	0.000158	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TP53—glaucoma	7.65e-06	0.000158	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NGFR—glaucoma	7.56e-06	0.000156	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—MTHFR—glaucoma	7.53e-06	0.000156	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TXN—glaucoma	7.51e-06	0.000155	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SMO—glaucoma	7.31e-06	0.000151	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NTRK1—glaucoma	7.18e-06	0.000149	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—C3—glaucoma	7.12e-06	0.000147	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ABCA1—glaucoma	7.12e-06	0.000147	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CYP1B1—glaucoma	7.12e-06	0.000147	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—NOS3—glaucoma	7.08e-06	0.000147	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NGFR—glaucoma	7.06e-06	0.000146	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—APOE—glaucoma	7.01e-06	0.000145	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GSTM1—glaucoma	7.01e-06	0.000145	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CAV1—glaucoma	6.95e-06	0.000144	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NTRK1—glaucoma	6.71e-06	0.000139	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NTRK2—glaucoma	6.68e-06	0.000138	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CDKN2B—glaucoma	6.62e-06	0.000137	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PTGS2—glaucoma	6.48e-06	0.000134	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EDN1—glaucoma	6.35e-06	0.000131	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—VEGFA—glaucoma	6.24e-06	0.000129	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—TP53—glaucoma	6.21e-06	0.000129	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—MTHFR—glaucoma	6.2e-06	0.000128	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CDKN2B—glaucoma	6.18e-06	0.000128	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EDN1—glaucoma	5.93e-06	0.000123	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NGF—glaucoma	5.83e-06	0.000121	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTT1—glaucoma	5.83e-06	0.000121	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—TP53—glaucoma	5.8e-06	0.00012	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—APOE—glaucoma	5.77e-06	0.000119	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NGFR—glaucoma	5.73e-06	0.000119	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CAV1—glaucoma	5.71e-06	0.000118	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSTM1—glaucoma	5.69e-06	0.000118	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—C3—glaucoma	5.55e-06	0.000115	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NGF—glaucoma	5.45e-06	0.000113	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NTRK1—glaucoma	5.45e-06	0.000113	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—NOS3—glaucoma	5.25e-06	0.000109	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—C3—glaucoma	5.18e-06	0.000107	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—APOE—glaucoma	5.16e-06	0.000107	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CAV1—glaucoma	5.12e-06	0.000106	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—MTHFR—glaucoma	5.03e-06	0.000104	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CDKN2B—glaucoma	5.02e-06	0.000104	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FN1—glaucoma	4.87e-06	0.000101	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—APOE—glaucoma	4.82e-06	9.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EDN1—glaucoma	4.82e-06	9.97e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—BAD—glaucoma	4.81e-06	9.95e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PTGS2—glaucoma	4.8e-06	9.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CAV1—glaucoma	4.78e-06	9.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TP53—glaucoma	4.71e-06	9.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—APOE—glaucoma	4.68e-06	9.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CAV1—glaucoma	4.64e-06	9.6e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP1B1—glaucoma	4.64e-06	9.6e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ABCA1—glaucoma	4.64e-06	9.6e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FN1—glaucoma	4.55e-06	9.41e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—BAD—glaucoma	4.49e-06	9.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NGF—glaucoma	4.43e-06	9.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—NOS3—glaucoma	4.32e-06	8.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—C3—glaucoma	4.21e-06	8.71e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PTGS2—glaucoma	3.95e-06	8.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APOE—glaucoma	3.92e-06	8.11e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CAV1—glaucoma	3.88e-06	8.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NOS3—glaucoma	3.87e-06	8e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTM1—glaucoma	3.71e-06	7.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FN1—glaucoma	3.69e-06	7.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—BAD—glaucoma	3.65e-06	7.55e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NOS3—glaucoma	3.61e-06	7.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—NOS3—glaucoma	3.51e-06	7.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CDKN1B—glaucoma	3.35e-06	6.93e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—MTHFR—glaucoma	3.28e-06	6.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PTGS2—glaucoma	3.21e-06	6.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CDKN1B—glaucoma	3.13e-06	6.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MMP9—glaucoma	3.1e-06	6.42e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—APOE—glaucoma	3.05e-06	6.32e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CAV1—glaucoma	3.02e-06	6.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NOS3—glaucoma	2.93e-06	6.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MMP9—glaucoma	2.9e-06	6e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—VEGFA—glaucoma	2.79e-06	5.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—VEGFA—glaucoma	2.6e-06	5.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CDKN1B—glaucoma	2.54e-06	5.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MMP9—glaucoma	2.35e-06	4.87e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NOS3—glaucoma	2.29e-06	4.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VEGFA—glaucoma	2.11e-06	4.37e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TP53—glaucoma	2.11e-06	4.36e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PTGS2—glaucoma	2.09e-06	4.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TP53—glaucoma	1.97e-06	4.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TP53—glaucoma	1.6e-06	3.31e-05	CbGpPWpGaD
